# 2025年11月12日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 变革儿科癫痫治疗：一项领先的单中心研究对迷走神经治疗结局的真实世界洞见

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41217293](https://pubmed.ncbi.nlm.nih.gov/41217293)
**期刊：** Epilepsia
**PMID：** 41217293
**DOI：** 10.1111/epi.70002

### 第一部分 原文与翻译

**英文原标题：** Transforming pediatric epilepsy care: Real-world insights from a leading single-center study on vagus nerve treatment outcomes.

**英文摘要原文：**
OBJECTIVE: Vagus nerve stimulation (VNS) is utilized increasingly in the management of drug-resistant epilepsy (DRE), yet its long-term efficacy and prognostic indicators remain incompletely understood. This study evaluated both short- and long-term seizure outcomes in pediatric patients with DRE following VNS therapy, with a focus on the influence of stimulation parameters and the potential predictors of a favorable response.

METHODS: A retrospective review was conducted of pediatric patients who underwent implantation of a vagus nerve stimulator between 2003 and 2023 at a Level 4 epilepsy center. Seizure burden and non-seizure outcomes were assessed at multiple follow-up intervals. Outcomes were further analyzed by seizure type and variations in VNS stimulation parameters.

RESULTS: A total of 400 pediatric patients received VNS therapy, with a mean follow-up duration of 4.92 years (median 3.5 years; interquartile range [IQR] = 2 to 6.97 years). Seizure frequency improved progressively, with a responder rate (RR, defined as ≥50% reduction in seizure frequency) reaching 90.5% at last follow-up, and 20.5% of patients achieving seizure freedom. Subgroup analysis revealed RRs of 88.6% for generalized epilepsy, 93.1% for focal epilepsy, and 90% for combined epilepsy, with the highest rate of seizure freedom observed for focal epilepsy (31.6%, p = .006; Bonferroni-adjusted p* = .048). Early vagus nerve stimulator implantation (≤2 years from seizure onset) was associated with improved outcomes (p = .034; p* = .272). Higher stimulation parameters, particularly ultra-rapid duty cycle, correlated with greater seizure reduction (p = .018; p* = .144). Subjective quality of life improvement was reported in 90% of patients, including enhancement in attention, development, and academic performance. VNS therapy was well tolerated, with mostly mild adverse events; the most common was obstructive sleep apnea, which was managed through parameter adjustments.

SIGNIFICANCE: This study underscores the long-term efficacy and safety of VNS therapy in pediatric DRE, particularly in patients receiving higher duty cycle and output current. Early implantation, focal epilepsy, and optimized stimulation parameters were associated with better seizure control and substantial subjective improvements in quality of life.

**中文摘要译文：**
目的：迷走神经刺激术（VNS）越来越多地用于治疗耐药性癫痫（DRE），但其长期疗效和预后指标尚不完全清楚。本研究旨在评估接受VNS治疗的DRE患儿的短期和长期癫痫结局，重点关注刺激参数的影响以及良好反应的潜在预测因素。

方法：本研究对2003年至2023年间在一家四级癫痫中心接受迷走神经刺激器植入术的儿科患者进行了回顾性分析。在多个随访时间点评估了癫痫负荷和非癫痫结局。研究还根据癫痫类型和VNS刺激参数的变化对结局进行了进一步分析。

结果：共有400名儿科患者接受了VNS治疗，平均随访时间为4.92年（中位随访时间3.5年；四分位距[IQR] = 2至6.97年）。癫痫发作频率逐渐改善，在末次随访时，有效率（RR，定义为癫痫发作频率减少≥50%）达到90.5%，且有20.5%的患者实现无癫痫发作。亚组分析显示，全面性癫痫的有效率为88.6%，局灶性癫痫为93.1%，合并性癫痫为90%，其中局灶性癫痫的无发作率最高（31.6%，p = .006；Bonferroni校正后 p* = .048）。早期迷走神经刺激器植入（癫痫起病后≤2年）与改善的结局相关（p = .034；p* = .272）。更高的刺激参数，尤其是超快速占空比，与更大幅度的癫痫减少相关（p = .018；p* = .144）。据报告，90%的患者主观生活质量得到改善，包括注意力、发育和学业表现的提升。VNS治疗耐受性良好，不良事件多为轻度；最常见的是阻塞性睡眠呼吸暂停，可通过调整参数进行管理。

意义：本研究强调了VNS疗法在儿科DRE中的长期有效性和安全性，尤其是在接受较高占空比和输出电流的患者中。早期植入、局灶性癫痫以及优化的刺激参数与更好的癫痫控制和主观生活质量的显著改善相关。

### 第二部分 AI 大师评价

本研究通过一项大规模、长周期的单中心回顾性分析，系统评估了迷走神经刺激术（VNS）治疗儿科耐药性癫痫的长期效果。核心发现揭示了高达90.5%的患者有效率，并明确了早期植入、局灶性癫痫类型及优化的高刺激参数（如超快速占空比）是实现更佳癫痫控制的关键预测因素。这项研究为VNS在儿科领域的临床应用提供了强有力的真实世界证据，尤其对治疗时机选择和参数个体化调整具有重要的指导价值，尽管其单中心和回顾性设计可能限制了结论的普适性。

---

速递结束，祝您工作愉快！